Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

DECISION

Financiado

Cerrado

DECOMPENSATED CIRRHOSIS IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON...

DECOMPENSATED CIRRHOSIS IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. development of ascites, hepatic encephalopathy, and/or gastrointestinal hemorrhage, and its progre... ver más

30/09/2025

EF CLIF

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 33 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-12-05

SC1-BHC-02-2019: Systems approaches for the discover...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

33 Participantes

EF CLIF

1.23M€ | Lider

CAF RAIL DIGITAL SERVICES SL

762.10K€ | Participante

COBRA INSTALACIONES Y SERVIC...

2.79M€ | Participante

ESTEYCO ENERGIA

481.02K€ | Participante

Proyectos interesantes

A-TANGO

Medical Technol...

Data Science

6M€ Cerrado

LIVERAIM

Medical Technol...

Data Science

25M€ Cerrado

HEPCIR

Medical Technol...

Data Science

2M€ Cerrado

MICROB-PREDICT

Medical Technol...

Data Science

15M€ Cerrado

DILITEST

Medical Technol...

Data Science

71K€ Cerrado

D-SOLVE

Medical Technol...

Data Science

7M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 69 meses Fecha Inicio: 2019-12-05
Fecha Fin: 2025-09-30

Líder del proyecto

EUROPEAN FOUNDATION FOR THE STUDY OF CHRONIC... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. This mortality is mainly due to cirrhosis decompensation, i.e. development of ascites, hepatic encephalopathy, and/or gastrointestinal hemorrhage, and its progression to acute-on-chronic liver failure (ACLF). Patients with decompensated cirrhosis receive many treatments such as intravenous and oral absorbable antibiotics, oral non-absorbable antibiotics, albumin, proton-pump inhibitors, laxatives, diuretics, betablockers, vasoconstrictors, statins, anticoagulants, steroids and antiviral agents. Despite these multiple treatments, ACLF or mortality in patients with decompensation of cirrhosis remains high (15% at day 28, 28% at day 90) because of large interindividual variability in precipitating events, in clinical presentation and in response to treatment. This heterogeneity calls for treatment personalization according to underlying mechanisms. The objective of DECISION is to enhance our understanding, at systems level, of the pathophysiology of decompensation of cirrhosis leading to ACLF or death to decrease patients’ mortality at day 28. First, DECISION will improve our knowledge of the pathophysiology of decompensation of cirrhosis by integrating results of high-throughput multi-omic profiling with comprehensive clinical data from 2,200 fully characterized patients (more than 8,600 time points) with available standardized biological samples. Second, we will identify novel combinatorial therapies for patients with decompensation of cirrhosis to prevent death. We will refine these therapies in new and/or optimized animal models and then test the best combination in high risk patients in a phase II clinical trial built in DECISION. Third, we will develop 2 tests: one predicting outcome of patients with decompensation of cirrhosis when treated with standard treatment (prognostic test); and the other identifying patients who will respond to the novel combinatorial therapy (test for response).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores